Ultra-High Resolution Mass Spectrometer for Biomedical Research
用于生物医学研究的超高分辨率质谱仪
基本信息
- 批准号:7839335
- 负责人:
- 金额:$ 270.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-04-15 至 2011-10-14
- 项目状态:已结题
- 来源:
- 关键词:AgingAlzheimer&aposs DiseaseAmino Acid SequenceAmyotrophic Lateral SclerosisArtsBiological MarkersBiomedical ResearchCellsDetectionDevicesDiseaseDissociationElectron TransportElectronsFourier transform ion cyclotron resonanceFundingHealthHumanHuntington DiseaseInstitutionIonsLigandsMalignant NeoplasmsMeasurementMembrane ProteinsMethodsMolecularNeurodegenerative DisordersParkinson DiseasePeptide Sequence DeterminationPeptidesPhosphorylationPost-Translational Protein ProcessingProteinsResearchResearch PersonnelResearch SupportResolutionScientistSystemTrainingbasehuman diseaseimprovedinstrumentinstrumentationmagnetic fieldmass spectrometeroutcome forecastprotein structurepublic health relevanceresearch studysmall moleculetandem mass spectrometryultra high resolution
项目摘要
DESCRIPTION (provided by applicant): A high-magnetic field, ultra-high resolution Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometer with capabilities for enhanced top-down protein sequencing and metabolite detection is requested. This instrument will be a vital component to support the research aims of over 11 NIH-funded projects. The studies involve a variety of protein structure-related research, including the determination of protein-protein and protein-ligand interactions, protein phosphorylation, membrane protein structure, and the identification of protein biomarkers for disease detection and prognosis. The research will impact a range of human health issues, including aging, neurodegenerative diseases, such as Huntington's disease, Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS), and cancer. The ultra-high resolution FT-ICR mass spectrometer will be capable of sub-parts-per-million to parts-per-billion mass measurement accuracy for intact peptides/proteins and product ions derived from tandem mass spectrometry (MS/MS) experiments, and small molecule metabolite identification. It will have capabilities for multistage MS-n experiments (n greater than 2) to be conducted in the ICR trapping/detection device, thus permitting advanced top-down analysis using infrared multiphoton dissociation (IRMPD) and electron capture dissociation (ECD) for efficient ion activation and dissociation in the ICR cell. Electron transfer dissociation (ETD) will be available as an alternative dissociation method. Both ETD and ECD greatly improve the ability to dissociate intact proteins to derive complete sequence information, as well as holding the promise of direct detection of post-translational modifications. The instrument will be a centerpiece and will be supported and administered by the Molecular Instrumentation Center at UCLA, and it will serve researchers from across the institution and nearby institutions.
PUBLIC HEALTH RELEVANCE: The new instrumentation will benefit a wide range of biomedical studies. The high sensitivity and high resolution capabilities of the system will provide a new means to identify the mechanistic basis of a number of human diseases, such as neurodegenerative disorders, and it may be used to identify new protein markers of cancer. The availability of this new, state-of-the-art mass spectrometer will require highly trained scientists to be hired and maintained for its operational use.
描述(由申请方提供):需要一种高磁场、超高分辨率傅里叶变换离子回旋共振(FT-ICR)质谱仪,具有增强的自上而下蛋白质测序和代谢物检测能力。该工具将成为支持超过11个NIH资助项目的研究目标的重要组成部分。这些研究涉及各种蛋白质结构相关的研究,包括蛋白质-蛋白质和蛋白质-配体相互作用的测定、蛋白质磷酸化、膜蛋白结构以及用于疾病检测和预后的蛋白质生物标志物的鉴定。这项研究将影响一系列人类健康问题,包括衰老、神经退行性疾病,如亨廷顿病、阿尔茨海默病、帕金森病和肌萎缩侧索硬化症(ALS),以及癌症。超高分辨率FT-ICR质谱仪将能够对来自串联质谱(MS/MS)实验的完整肽/蛋白质和产物离子以及小分子代谢物鉴定进行百万分之几至十亿分之几的质量测量准确度。它将具有在ICR捕获/检测装置中进行多级MS-n实验(n大于2)的能力,从而允许使用红外多光子解离(IRMPD)和电子捕获解离(ECD)进行先进的自上而下的分析,以在ICR室中进行有效的离子活化和解离。电子转移解离(ETD)将可作为替代解离方法。ETD和ECD都大大提高了解离完整蛋白质以获得完整序列信息的能力,并有望直接检测翻译后修饰。该仪器将是一个核心,将由加州大学洛杉矶分校的分子仪器中心支持和管理,它将为整个机构和附近机构的研究人员提供服务。
公共卫生相关性:新仪器将有利于广泛的生物医学研究。该系统的高灵敏度和高分辨率能力将提供一种新的手段来识别许多人类疾病的机制基础,例如神经退行性疾病,并且它可用于识别癌症的新蛋白质标记物。这种新的、最先进的质谱仪的可用性将需要雇用和维持训练有素的科学家,以供其业务使用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Joseph A Loo其他文献
Joseph A Loo的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Joseph A Loo', 18)}}的其他基金
Advancing Mass Spectrometry Analyses of Proteins, Assemblies, and Proteoforms
推进蛋白质、组装体和蛋白质形式的质谱分析
- 批准号:
10654823 - 财政年份:2022
- 资助金额:
$ 270.99万 - 项目类别:
Advancing Mass Spectrometry Analyses of Proteins, Assemblies, and Proteoforms
推进蛋白质、组装体和蛋白质形式的质谱分析
- 批准号:
10405346 - 财政年份:2022
- 资助金额:
$ 270.99万 - 项目类别:
MALDI TOF/TOF Mass Spectrometer for Imaging Thin Tissue Sections
用于薄组织切片成像的 MALDI TOF/TOF 质谱仪
- 批准号:
7792167 - 财政年份:2010
- 资助金额:
$ 270.99万 - 项目类别:
Impact of Non-canonical Decoding on the Proteome
非规范解码对蛋白质组的影响
- 批准号:
7915166 - 财政年份:2008
- 资助金额:
$ 270.99万 - 项目类别:
Impact of Non-canonical Decoding on the Proteome
非规范解码对蛋白质组的影响
- 批准号:
8129498 - 财政年份:2008
- 资助金额:
$ 270.99万 - 项目类别:
Impact of Non-canonical Decoding on the Proteome
非规范解码对蛋白质组的影响
- 批准号:
7664277 - 财政年份:2008
- 资助金额:
$ 270.99万 - 项目类别:
Impact of Non-canonical Decoding on the Proteome
非规范解码对蛋白质组的影响
- 批准号:
7515171 - 财政年份:2008
- 资助金额:
$ 270.99万 - 项目类别:














{{item.name}}会员




